Diosynth Biotechnology has entered into a long-term commercial supply agreement with Dendreon Corp. for the manufacture of the recombinant antigen component of Provenge, Dendreon’s investigational immunotherapy for prostate cancer. The product will be manufactured for market launch and commercial sale in the Diosynth Biotechnology facility in North Carolina. Subsequent manufacturing may also be done at Diosynth’s large-scale cell culture facilities in the Netherlands. This agree...